Search Results

There are 11466 results for: content related to: First-line sunitinib plus FOLFIRI in J apanese patients with unresectable/metastatic colorectal cancer: A phase II study

  1. You have full text access to this OnlineOpen article
    Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment

    Cancer Science

    Volume 106, Issue 2, February 2015, Pages: 160–170, Gökçe Hatipoglu, Stefan W. Hock, Ruth Weiss, Zheng Fan, Tina Sehm, Ali Ghoochani, Michael Buchfelder, Nicolai E. Savaskan and Ilker Y. Eyüpoglu

    Version of Record online : 15 FEB 2015, DOI: 10.1111/cas.12580

  2. You have free access to this content
    Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662

    British Journal of Clinical Pharmacology

    Volume 79, Issue 5, May 2015, Pages: 809–819, Huixin Yu, Neeltje Steeghs, Jacqueline S. L. Kloth, Djoeke de Wit, J. G. Coen van Hasselt, Nielka P. van Erp, Jos H. Beijnen, Jan H. M. Schellens, Ron H. J. Mathijssen and Alwin D. R. Huitema

    Version of Record online : 22 APR 2015, DOI: 10.1111/bcp.12550

  3. You have full text access to this Open Access content
    UGT1A1*6,1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan

    Cancer Science

    Volume 104, Issue 12, December 2013, Pages: 1662–1669, Shoichi Hazama, Hideyuki Mishima, Ryouichi Tsunedomi, Yusuke Okuyama, Takeshi Kato, Ken-ichi Takahashi, Hiroshi Nozawa, Hideaki Ando, Michiya Kobayashi, Hiroyoshi Takemoto, Naoki Nagata, Shinsuke Kanekiyo, Yuka Inoue, Yoshihiko Hamamoto, Yusuke Fujita, Yuji Hinoda, Naoko Okayama, Koji Oba, Jun-ichi Sakamoto and Masaaki Oka

    Version of Record online : 27 OCT 2013, DOI: 10.1111/cas.12283

  4. You have full text access to this OnlineOpen article
    Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G

    Cancer Science

    Volume 107, Issue 12, December 2016, Pages: 1843–1850, Kohei Shitara, Kimio Yonesaka, Tadamichi Denda, Kentaro Yamazaki, Toshikazu Moriwaki, Masahiro Tsuda, Toshimi Takano, Hiroyuki Okuda, Tomohiro Nishina, Kazuko Sakai, Kazuto Nishio, Shoji Tokunaga, Takeharu Yamanaka, Narikazu Boku, Ichinosuke Hyodo and Kei Muro

    Version of Record online : 29 DEC 2016, DOI: 10.1111/cas.13098

  5. You have full text access to this OnlineOpen article
    Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer

    Cancer Science

    Volume 105, Issue 10, October 2014, Pages: 1321–1326, Takuji Okusaka, Masafumi Ikeda, Akira Fukutomi, Tatsuya Ioka, Junji Furuse, Shinichi Ohkawa, Hiroyuki Isayama and Narikazu Boku

    Version of Record online : 29 SEP 2014, DOI: 10.1111/cas.12501

  6. You have full text access to this Open Access content
    Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy

    Cancer Science

    Volume 103, Issue 4, April 2012, Pages: 791–796, Yao-Yu Hsieh, Cheng-Hwai Tzeng, Ming-Huang Chen, Po-Min Chen and Wei-Shu Wang

    Version of Record online : 22 FEB 2012, DOI: 10.1111/j.1349-7006.2012.02225.x

  7. You have full text access to this OnlineOpen article
    Overexpression of chemokine receptor CXCR2 and ligand CXCL7 in liver metastases from colon cancer is correlated to shorter disease-free and overall survival

    Cancer Science

    Volume 106, Issue 3, March 2015, Pages: 262–269, Thibault Desurmont, Nicolas Skrypek, Alain Duhamel, Nicolas Jonckheere, Guillaume Millet, Emmanuelle Leteurtre, Pierre Gosset, Belinda Duchene, Nassima Ramdane, Mohamed Hebbar, Isabelle Van Seuningen, François-René Pruvot, Guillemette Huet and Stéphanie Truant

    Version of Record online : 5 MAR 2015, DOI: 10.1111/cas.12603

  8. You have full text access to this OnlineOpen article
    Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants

    Cancer Science

    Volume 105, Issue 1, January 2014, Pages: 117–125, Jie Zhao, Haitian Quan, Yongping Xu, Xiangqian Kong, Lu Jin and Liguang Lou

    Version of Record online : 4 JAN 2014, DOI: 10.1111/cas.12320

  9. You have full text access to this Open Access content
    Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells

    Cancer Science

    Volume 104, Issue 8, August 2013, Pages: 1052–1061, Yu Zhu, Le Xu, Jianping Zhang, Xiaoyi Hu, Yujun Liu, Hankun Yin, Tao Lv, Heng Zhang, Li Liu, Huimin An, Haiou Liu, Jiejie Xu and Zongming Lin

    Version of Record online : 16 MAY 2013, DOI: 10.1111/cas.12176

  10. Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function

    The Journal of Clinical Pharmacology

    Volume 50, Issue 4, April 2010, Pages: 472–481, Reza Khosravan, Melvin Toh, May Garrett, JoAnn La Fargue, Grace Ni, Thomas C. Marbury, Suzanne K. Swan, Norman M. Lunde and Carlo L. Bello

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009347868

  11. You have full text access to this Open Access content
    Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo

    Cancer Science

    Volume 104, Issue 7, July 2013, Pages: 896–903, Makito Suzuki, Hideki Makinoshima, Shingo Matsumoto, Ayako Suzuki, Sachiyo Mimaki, Koutatsu Matsushima, Kiyotaka Yoh, Koichi Goto, Yutaka Suzuki, Genichiro Ishii, Atsushi Ochiai, Koji Tsuta, Tatsuhiro Shibata, Takashi Kohno, Hiroyasu Esumi and Katsuya Tsuchihara

    Version of Record online : 12 MAY 2013, DOI: 10.1111/cas.12175

  12. Quantitation of sunitinib, an oral multitarget tyrosine kinase inhibitor, and its metabolite in urine samples by nonaqueous capillary electrophoresis time of flight mass spectrometry

    ELECTROPHORESIS

    Volume 36, Issue 14, July 2015, Pages: 1580–1587, Juana Rodríguez, Gregorio Castañeda, Lorena Muñoz and Jose C. Villa

    Version of Record online : 20 MAY 2015, DOI: 10.1002/elps.201400588

  13. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography–tandem mass spectrometry: application to a pharmacokinetic study

    Biomedical Chromatography

    Volume 26, Issue 11, November 2012, Pages: 1315–1324, Rana Rais, Ming Zhao, Ping He, Linping Xu, John F. Deeken and Michelle A. Rudek

    Version of Record online : 18 JAN 2012, DOI: 10.1002/bmc.2697

  14. You have full text access to this Open Access content
    Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients

    Cancer Science

    Volume 103, Issue 8, August 2012, Pages: 1405–1413, Kosuke Yamaguchi, Hiroki Chikumi, Asuka Shimizu, Miyako Takata, Naoki Kinoshita, Kiyoshi Hashimoto, Masaki Nakamoto, Shinji Matsunaga, Jun Kurai, Naomi Miyake, Shingo Matsumoto, Masanari Watanabe, Akira Yamasaki, Tadashi Igishi, Naoto Burioka and Eiji Shimizu

    Version of Record online : 9 JUL 2012, DOI: 10.1111/j.1349-7006.2012.02330.x

  15. You have free access to this content
    Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

    International Journal of Cancer

    Volume 130, Issue 8, 15 April 2012, Pages: 1948–1959, Benedetto Farsaci, Jack P. Higgins and James W. Hodge

    Version of Record online : 8 AUG 2011, DOI: 10.1002/ijc.26219

  16. Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers

    Clinical Pharmacology & Therapeutics

    Volume 87, Issue 5, May 2010, Pages: 601–608, A Lindauer, P Di Gion, F Kanefendt, D Tomalik-Scharte, M Kinzig, M Rodamer, F Dodos, F Sörgel, U Fuhr and U Jaehde

    Version of Record online : 7 APR 2010, DOI: 10.1038/clpt.2010.20

    Corrected by:

    Corrigendum: CORRIGENDUM: Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers

    Vol. 88, Issue 4, 566, Version of Record online: 25 AUG 2010

  17. You have full text access to this OnlineOpen article
    Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib

    Journal of Cellular and Molecular Medicine

    Volume 19, Issue 2, February 2015, Pages: 430–441, Eva Juengel, Dana Kim, Jasmina Makarević, Michael Reiter, Igor Tsaur, Georg Bartsch, Axel Haferkamp and Roman A. Blaheta

    Version of Record online : 2 DEC 2014, DOI: 10.1111/jcmm.12471

  18. You have free access to this content
    Research Podium Abstracts

    Value in Health

    Volume 12, Issue 3, May 2009, Pages: A1–A19,

    Version of Record online : 15 APR 2009, DOI: 10.1111/j.1524-4733.2009.00537_1.x

  19. You have full text access to this Open Access content
    Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells

    Molecular Oncology

    Volume 6, Issue 5, October 2012, Pages: 530–541, Anabel Sorolla, Andrée Yeramian, Joan Valls, Xavier Dolcet, Laura Bergadà, Antoni Llombart-Cussac, Rosa Maria Martí, Xavier Matias-Guiu

    Version of Record online : 7 JUL 2012, DOI: 10.1016/j.molonc.2012.06.006

  20. You have free access to this content
    RESEARCH POSTER ABSTRACTS

    Value in Health

    Volume 13, Issue 7, November 2010, Pages: A250–A480,

    Version of Record online : 11 OCT 2010, DOI: 10.1111/j.1524-4733.2010.00791_2.x